매크로 컨텍스트

테마

K-Bio & Drug Development

핵심 동인

  • GLP-1 obesity treatment market TAM of $100B
  • Zepbound prescriptions growing 100%+ monthly
  • Oral GLP-1 orforglipron in Phase 3 trials
  • Alzheimer's donanemab launch upcoming

리스크

  • Elevated valuation at P/E 60x+
  • Persistent GLP-1 supply shortage
  • Competitor entry (Amgen, Pfizer, etc.)
  • Potential adverse effect issues

애널리스트 컨센서스

최저 830 USD최고 1,500 USD
현재가컨센서스 목표가

2026. 6. 15. 기준

증권사애널리스트목표가투자의견
투자 기간: 12개월

모니터링 트리거

핵심 지표

  • Mounjaro/Zepbound quarterly revenue
  • GLP-1 prescription growth rate
  • Orforglipron clinical progress
  • Gross margin trend

리뷰 트리거

  • GLP-1 revenue QoQ growth below 5%
  • Competitor GLP-1 FDA approval
  • Revenue miss due to supply shortage

무효화 조건

  • GLP-1 safety issues trigger FDA warning
  • Orforglipron clinical failure
  • Market share drops below 30% in key markets

Related ETFs

ETFs covering the same theme as LLY — alternatives when direct holding is constrained or diversification is preferred

All ETFs

Comments

생성: 2026. 2. 24.수정: 2026. 2. 24.가격 기준: 2026. 6. 15.